Qualigen Therapeutics is strategically preparing to acquire high-quality assets, including leading cryptocurrencies like Bitcoin, Ethereum, and Solana, as well as sectors such as AI, RWA, and oracles, during this market correction.

The company views the recent market downturn as a healthy correction that offers an opportunity to build a stronger portfolio and facilitate industry restructuring.

In addition to asset accumulation, Qualigen is focusing on strategic M&A, targeting core blue-chip blockchain projects and innovative startups in high-growth sectors to expand its technological and market footprint.

A short-term liquidity crisis and a brief unpegging of USDe contributed to about 10-15% of liquidations, highlighting risks associated with synthetic assets during the downturn.

The unpegging of Ethena's USDe played a significant role in amplifying liquidations, exposing vulnerabilities in synthetic asset stability during the market stress.

Qualigen has established infrastructure including USD settlement, bank accounts, and crypto custody, but has yet to make any cryptocurrency purchases, planning to begin strategic acquisitions next week.

The recent market decline is characterized as a 'stress test' caused by excessive leverage and structural vulnerabilities, rather than a fundamental collapse, paving the way for healthier valuation and industry restructuring.

The company's SMART Investment Framework guides its risk management and asset allocation, combining passive tracking of top cryptocurrencies with active strategies involving hedging instruments like stablecoins, options, and structured products.

Qualigen employs an 80/20 passive/active asset allocation model, with active management driven by a quantitative scoring system and risk hedging tools to navigate market volatility.

To support its growth, Qualigen plans to expand asset management through private funds and ETFs, and is establishing a New York office to facilitate strategic initiatives.

The recent crypto market downturn involved a $16 billion liquidation of leveraged positions, mainly long positions, triggered by geopolitical tensions and macroeconomic factors, including Trump's threat to impose tariffs on China.

Qualigen Therapeutics has launched its C10 Cryptocurrency Asset Treasury (DAT) and plans to begin purchases next week, viewing the recent decline as an opportunity rather than a setback.

Despite short-term turbulence, Qualigen maintains a long-term bullish outlook on the crypto market, driven by macroeconomic support, regulatory developments, and technological advancements in AI and Web3, seeing the current correction as an ideal entry point for expansion.